Differential expression and enzymatic activity of DPPIV/CD26 affects migration ability of cervical carcinoma cells

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Beckenkamp, Aline ^a   Willig, Júlia Biz ^a   Santana, Danielle Bertodo ^a   Nascimento, Jéssica ^a   Paccez, Juliano Domiraci ^b   Zerbini, Luiz Fernando ^b   Bruno, Alessandra Nejar ^c   Pilger, Diogo André ^a   Wink, Márcia Rosângela ^d   Buffon, Andréia ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^c INSTITUTO FEDERAL DE EDUCAÇÃO   (Brazil)

^d UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; LACTATE DEHYDROGENASE; SITAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DPP4 PROTEIN, HUMAN; MEMBRANE PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; C33A CERVICAL CANCER CELL LINE; CELL ADHESION; CELL MEMBRANE; CELL MIGRATION; CELL SURFACE; CELL VIABILITY; CERVICAL CANCER CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HACAT CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; HYDROLYSIS; KERATINOCYTE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SIHA CERVICAL CANCER CELL LINE; CARCINOMA; CELL MOTION; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

CARCINOMA; CELL ADHESION; CELL LINE, TUMOR; CELL MEMBRANE; CELL MOVEMENT; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HELA CELLS; HUMANS; KERATINOCYTES; MEMBRANE GLYCOPROTEINS; SITAGLIPTIN PHOSPHATE; UTERINE CERVICAL NEOPLASMS;

EID: 84941914681     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134305     Document Type: Article

References (51)

1. Rama CH, Roteli-Martins CM, Derchain SF, Longatto-Filho A, Gontijo RC, Sarian LO, et al. Prevalence of genital HPV infection among women screened for cervical cancer. Rev Saude Publica. 2008; 42: 123-130. PMID: 18200349.
2. de Cremoux P, de la Rochefordiere A, Savignoni A, Kirova Y, Alran S, Fourchotte V, et al. Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype. Int J Cancer. 2009; 124: 778-782. doi: 10.1002/ijc.24075 PMID: 19035459.
3. Zagouri F, Sergentanis TN, Chrysikos D, Filipits M, Bartsch R. Molecularly targeted therapies in cervical cancer. A systematic review. Gynecol Oncol. 2012; 126: 291-303. doi: 10.1016/j.ygyno.2012.04.007 PMID: 22504292.
4. Yu DM, Yao TW, Chowdhury S, Nadvi NA, Osborne B, Church WB, et al. The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J. 2010; 277: 1126-1144. doi: 10.1111/j.1742-4658.2009. 07526.x PMID: 20074209.
5. Havre PA, Abe M, Urasaki Y, Ohnuma K, Morimoto C, Dang NH. The role of CD26/dipeptidyl peptidase IV in cancer. Front Biosci. 2008; 13: 1634-1645. PMID: 17981655.
6. Cordero OJ, Salgado FJ, Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother. 2009; 58: 1723-1747. doi: 10.1007/s00262-009-0728-1 PMID: 19557413.
7. Eric-Nikolic A, Matic IZ, Dordevic M, Milovanovic Z, Markovic I, Dzodic R, et al. Serum DPPIV activity and CD26 expression on lymphocytes in patients with benign or malignant breast tumors. Immunobiology. 2011; 216: 942-946. doi: 10.1016/j.imbio.2011.01.005 PMID: 21281985.
8. Lambeir AM, Diaz Pereira JF, Chacon P, Vermeulen G, Heremans K, Devreese B, et al. A prediction of DPP IV/CD26 domain structure from a physico-chemical investigation of dipeptidyl peptidase IV (CD26) from human seminal plasma. Biochim Biophys Acta. 1997; 1340: 215-226. PMID: 9252108.
9. Iwaki-Egawa S, Watanabe Y, Kikuya Y, Fujimoto Y. Dipeptidyl peptidase IV from human serum: purification, characterization, and N-terminal amino acid sequence. J Biochem. 1998; 124: 428-433. PMID: 9685737.
10. De Meester I, Korom S, Van Damme J, Scharpe S. CD26, let it cut or cut it down. Immunol Today. 1999; 20: 367-375. PMID: 10431157.
11. Durinx C, Lambeir AM, Bosmans E, Falmagne JB, Berghmans R, Haemers A, et al. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem. 2000; 267: 5608-5613. PMID: 10951221.
12. Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp. 1997; 186: 1865-1872.
13. Shioda T, Kato H, Ohnishi Y, Tashiro K, Ikegawa M, Nakayama EE, et al. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci U S A. 1998; 95: 6331-6336. PMID: 9600965.
14. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 1999; 85: 9-24. PMID: 10588446.
15. Proost P, Struyf S, Schols D, Opdenakker G, Sozzani S, Allavena P, et al. Truncation of macrophagederived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem. 1999; 274: 3988-3993. PMID: 9933589.
16. Hinke SA, Pospisilik JA, Demuth HU, Mannhart S, Kuhn-Wache K, Hoffmann T, et al. Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs. J Biol Chem. 2000; 275: 3827-3834. PMID: 10660533.
17. Lambeir AM, Proost P, Durinx C, Bal G, Senten K, Augustyns K, et al. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem. 2001; 276: 29839-29845. PMID: 11390394.
18. Dong RP, Tachibana K, Hegen M, Munakata Y, Cho D, Schlossman SF, et al. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. J Immunol. 1997; 159: 6070-6076. PMID: 9550406.
19. Bauvois B. A collagen-binding glycoprotein on the surface of mouse fibroblasts is identified as dipeptidyl peptidase IV. Biochem J. 1988; 252: 723-731. PMID: 2901831.
20. Hanski C, Huhle T, Gossrau R, Reutter W. Direct evidence for the binding of rat liver DPP IV to collagen in vitro. Exp Cell Res. 1988; 178: 64-72. PMID: 2900773.
21. Loster K, Zeilinger K, Schuppan D, Reutter W. The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site. Biochem Biophys Res Commun. 1995; 217: 341-348. PMID: 8526932.
22. Cheng HC, Abdel-Ghany M, Elble RC, Pauli BU. Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. J Biol Chem. 1998; 273: 24207-24215. PMID: 9727044.
23. Cheng HC, Abdel-Ghany M, Pauli BU. A novel consensus motif in fibronectin mediates dipeptidyl peptidase IV adhesion and metastasis. J Biol Chem. 2003; 278: 24600-24607. PMID: 12716896.
24. Torimoto Y, Dang NH, Vivier E, Tanaka T, Schlossman SF, Morimoto C. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J Immunol. 1991; 147: 2514- 2517. PMID: 1680916.
25. Scanlan MJ, Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A. 1994; 91: 5657-5661. PMID: 7911242.
26. Gonzalez-Gronow M, Grenett HE, Weber MR, Gawdi G, Pizzo SV. Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells. Biochem J. 2001; 355: 397-407. PMID: 11284727.
27. Herrera C, Morimoto C, Blanco J, Mallol J, Arenzana F, Lluis C, et al. Comodulation of CXCR4 and CD26 in human lymphocytes. J Biol Chem. 2001; 276: 19532-19539. PMID: 11278278.
28. Arscott WT, LaBauve AE, May V, Wesley UV. Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation. Oncogene. 2009; 28: 479-491. doi: 10.1038/onc.2008.402 PMID: 18978811.
29. Zanoni TB, Tiago M, Faiao-Flores F, de Moraes Barros SB, Bast A, Hageman G, et al. Basic Red 51, a permitted semi-permanent hair dye, is cytotoxic to human skin cells: Studies in monolayer and 3D skin model using human keratinocytes (HaCaT). Toxicology letters. 2014; 227: 139-149. doi: 10.1016/j. toxlet.2014.03.007 PMID: 24657526.
30. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72: 248-254. PMID: 942051.
31. Zerbini LF, Wang Y, Cho JY, Libermann TA. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res. 2003; 63: 2206-2215. PMID: 12727841.
32. Buffon A, Ribeiro VB, Wink MR, Casali EA, Sarkis JJ. Nucleotide metabolizing ecto-enzymes in Walker 256 tumor cells: molecular identification, kinetic characterization and biochemical properties. Life Sci. 2007; 80: 950-958. PMID: 17169379.
33. Kirby M, Yu DM, O'Connor S, Gorrell MD. Inhibitor selectivity in the clinical application of dipeptidyl peptidase- 4 inhibition. Clin Sci (Lond). 2010; 118: 31-41.
34. Wang A, Dorso C, Kopcho L, Locke G, Langish R, Harstad E, et al. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor. BMC Pharmacol. 2012; 12:2. doi: 10.1186/1471- 2210-12-2 PMID: 22475049.
35. Gorrell MD. Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond). 2005; 108: 277-292.
36. Yu DM, Ajami K, Gall MG, Park J, Lee CS, Evans KA, et al. The in vivo expression of dipeptidyl peptidases 8 and 9. J Histochem Cytochem. 2009; 57: 1025-1040. doi: 10.1369/jhc.2009.953760 PMID: 19581630.
37. Maes MB, Lambeir AM, Gilany K, Senten K, Van der Veken P, Leiting B, et al. Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7). Biochem J. 2005; 386: 315-324. PMID: 15487984.
38. Wesley UV, Albino AP, Tiwari S, Houghton AN. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med. 1999; 190: 311-322. PMID: 10430620.
39. Kajiyama H, Kikkawa F, Suzuki T, Shibata K, Ino K, Mizutani S. Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. Cancer Res. 2002; 62: 2753-2757. PMID: 12019149.
40. Wesley UV, Tiwari S, Houghton AN. Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int J Cancer. 2004; 109: 855-866. PMID: 15027119.
41. Kikkawa F, Kajiyama H, Shibata K, Ino K, Nomura S, Mizutani S. Dipeptidyl peptidase IV in tumor progression. Biochim Biophys Acta. 2005; 1751: 45-51. PMID: 16054016.
42. Wesley UV, McGroarty M, Homoyouni A. Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway. Cancer Res. 2005; 65: 1325- 1334. PMID: 15735018.
43. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F. Involvement of DPPIV/CD26 in epithelial morphology and suppressed invasive ability in ovarian carcinoma cells. Ann N Y Acad Sci. 2006; 1086: 233-240. PMID: 17185520.
44. Busek P, Stremenova J, Sromova L, Hilser M, Balaziova E, Kosek D, et al. Dipeptidyl peptidase-IV inhibits glioma cell growth independent of its enzymatic activity. Int J Biochem Cell Biol. 2012; 44: 738- 747. doi: 10.1016/j.biocel.2012.01.011 PMID: 22306301.
45. Goscinski MA, Suo ZH, Nesland JM, Florenes VA, Giercksky KE. Dipeptidyl peptidase IV expression in cancer and stromal cells of human esophageal squamous cell carcinomas, adenocarcinomas and squamous cell carcinoma cell lines. APMIS. 2008; 116: 823-831. PMID: 19024603.
46. Cro L, Morabito F, Zucal N, Fabris S, Lionetti M, Cutrona G, et al. CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL. Hematol Oncol. 2009; 27: 140-147. doi: 10.1002/hon.888 PMID: 19247978.
47. Cordero OJ, Imbernon M, Chiara LD, Martinez-Zorzano VS, Ayude D, de la Cadena MP, et al. Potential of soluble CD26 as a serum marker for colorectal cancer detection. World J Clin Oncol. 2011; 2: 245- 261. doi: 10.5306/wjco.v2.i6.245 PMID: 21773075.
48. Matic IZ, Ethordic M, Grozdanic N, Damjanovic A, Kolundzija B, Eric-Nikolic A, et al. Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo. BMC Immunol. 2012; 13:48. doi: 10.1186/1471-2172-13-48 PMID: 22908963.
49. de Andrade CF, Bigni R, Pombo-de-Oliveira MS, Alves G, Pereira DA. CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia. J Enzyme Inhib Med Chem. 2009; 24: 708-714. PMID: 19469710.
50. De Chiara L, Rodriguez-Pineiro AM, Rodriguez-Berrocal FJ, Cordero OJ, Martinez-Ares D, Paez de la Cadena M. Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas. BMC Cancer. 2010; 10:333. doi: 10.1186/1471-2407-10-333 PMID: 20584285.
51. Kajiyama H, Kikkawa F, Khin E, Shibata K, Ino K, Mizutani S. Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Res. 2003; 63: 2278-2283. PMID: 12727850.